891 related articles for article (PubMed ID: 26803384)
1. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
[TBL] [Abstract][Full Text] [Related]
3. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
[TBL] [Abstract][Full Text] [Related]
4. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation.
Zhao Y; Lu Y; Qin Y
Int J Cardiol; 2018 Nov; 270():167-171. PubMed ID: 29903520
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
8. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
9. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
[TBL] [Abstract][Full Text] [Related]
10. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
Mugnai G; de Asmundis C; Iacopino S; Stroker E; Longobardi M; De Regibus V; Coutino-Moreno HE; Takarada K; Choudhury R; Abugattas de Torres JP; Storti C; Brugada P; Chierchia GB
Am J Cardiol; 2017 Jul; 120(2):223-229. PubMed ID: 28532773
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
13. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
[TBL] [Abstract][Full Text] [Related]
14. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
[TBL] [Abstract][Full Text] [Related]
15. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of Safety and Efficacy of Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists for Catheter Ablation of Atrial Fibrillation.
Elgendy AY; Mahtta D; Barakat AF; Abuzaid A; Mahmoud A; Mentias A; Mahmoud AN; Elgendy IY
Am J Cardiol; 2017 Nov; 120(10):1830-1836. PubMed ID: 28882334
[TBL] [Abstract][Full Text] [Related]
17. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
Vlachos K; Efremidis M; Bazoukis G; Letsas KP; Saplaouras A; Georgopoulos S; Karamichalakis N; Rokiza A; Sakellaropoulou A; Kolokathis AM; Efremidis T; Asvestas D; Sideris A
Clin Cardiol; 2017 Oct; 40(10):847-852. PubMed ID: 28561951
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
20. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H
Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]